Muscular Dystrophy Association's Annual ALS Fundraiser 'Night of ... - dofaq.co
Muscular Dystrophy Association's Annual ALS Fundraiser 'Night of ...
Muscular Dystrophy Association - 26 Feb 2024
MDA is the #1 health nonprofit advancing research, care and advocacy for people living with muscular dystrophy, ALS, and related neuromuscular diseases.
Interview: Steve Gleason, the author of the A.L.S. memoir ‘A Life Impossible’
The New York Times - 26 Apr 2024
Interview: Steve Gleason, the author of the A.L.S. memoir ‘A Life Impossible’ ...
ALS disease progression slowed in real-world setting with Qalsody
ALS News Today - 25 Apr 2024
ALS disease progression slowed in real-world setting with Qals ody ...
On the Horizon: A Robot to Assist ALS Patients - SBU News
Stony Brook News - 25 Apr 2024
On the Horizon: A Robot to Assist ALS Patients - SBU News ...
What we learned about ALS from the metabolic data of 600 people
Australian Institute for Bioengineering and Nanotechnology - 14 Apr 2024
What we learned about ALS from the metabolic data of 600 people ...
ALS writes down $258m drug stake, buys remainder for nothing
The Australian Financial Review - 25 Mar 2024
ALS writes down $258m drug stake, buys remainder for nothing ...
Examining Promising Phase 2b PARADIGM Findings of ALS Agent PrimeC: Merit Cudkowicz, MD, MSc
Neurology Live - 24 Apr 2024
Examining Promising Phase 2b PARADIGM Findings of ALS Agent PrimeC: Merit Cudkowicz, MD, MSc ...
Abnormal proteins found in the spinal fluid of people with ALS and frontotemporal dementia
National Institutes of Health (NIH) (.gov) - 31 Jan 2024
Abnormal proteins found in the spinal fluid of people with ALS and frontotemporal dementia ...
Evidence for disrupted copper availability in human spinal cord supports CuII(atsm) as a treatment option for sporadic ...
Nature.com - 11 Mar 2024
Evidence for disrupted copper availability in human spinal cord supports CuII(atsm) as a treatment option for sporadic ... ...
Here's Why ALS Drug Relyvrio Is Being Removed From Market—And What That Means For Patients
Forbes - 04 Apr 2024
Here's Why ALS Drug Relyvrio Is Being Removed From Market—And What That Means For Patients ...
PharmAust offers hope to MND patients with veterinary drug
The West Australian - 01 Apr 2024
PharmAust offers hope to MND patients with veterinary drug ...
Columbia Receives $15M for Ultra-Rare ALS Medicines Creation
Mirage News - 03 Apr 2024
Columbia Receives $15M for Ultra-Rare ALS Medicines Creation ...
Nuclear-import receptors as gatekeepers of pathological phase transitions in ALS/FTD - Molecular Neurodegeneration
Molecular Neurodegeneration - 22 Jan 2024
Nuclear-import receptors as gatekeepers of pathological phase transitions in ALS/FTD - Molecular Neurodegeneration ...
Coya Therapeutics CEO Discusses Next Steps Amid Positive Results from Coya 302 Trial for ALS Treatment
Pharmaceutical Executive - 24 Apr 2024
Coya Therapeutics CEO Discusses Next Steps Amid Positive Results from Coya 302 Trial for ALS Treatment ...
ALS 1H profit 2024: drug cutback hits margins but investors cheer outlook
The Australian Financial Review - 14 Nov 2023
ALS 1H profit 2024: drug cutback hits margins but investors cheer outlook ...
Nutrition, metabolic factors, could be key to solving ALS puzzle
Australian Institute for Bioengineering and Nanotechnology - 09 Nov 2023
Nutrition, metabolic factors, could be key to solving ALS puzzle ...
Certain spinal fluid biomarkers in ALS may predict responses to NurOwn
ALS News Today - 23 Apr 2024
Certain spinal fluid biomarkers in ALS may predict responses to NurOwn ...
A model of human neural networks reveals NPTX2 pathology in ALS and FTLD
Nature.com - 14 Feb 2024
A model of human neural networks reveals NPTX2 pathology in ALS and FTLD ...
Phase 2 trial testing dazucorilant in ALS patients now fully enrolled
ALS News Today - 24 Apr 2024
Phase 2 trial testing dazucorilant in ALS patients now fully enrolled ...
A fluid biomarker reveals loss of TDP-43 splicing repression in presymptomatic ALS–FTD
Nature.com - 26 Jan 2024
A fluid biomarker reveals loss of TDP-43 splicing repression in presymptomatic ALS–FTD ...